Stay updated with breaking news from Daniel Roling. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
An important external recognition of the potential of SINTAX medicines. We believe this puts EDP1815 and SINTAX medicines in a strong position as we move closer to realizing our vision to improve... | March 24, 2022
Durable and Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Bioscience’s Phase 2 Clinical Trial of Oral EDP1815 in Psoriasis - read this article along with other careers information, tips and advice on BioSpace
-18/30 patients maintained a PASI-50 or greater response at 24 weeks post-treatment- -9/20 patients experienced a deepening of response from PASI-50 to at least PASI-75 during post-treatment period- -No flare